Vaccine development for Alzheimer's disease: A shot of good news

Trends in Neurosciences

Volumn 24, Issue 6, 2001, Pages 305-307

  Ingram, Donald K ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABETA PEPTIDE VACCINE; UNCLASSIFIED DRUG; VACCINE;

ALZHEIMER DISEASE; DRUG SAFETY; INOCULATION; NONHUMAN; PLAQUE FORMING CELL; PRIORITY JOURNAL; SHORT SURVEY; VACCINATION; VACCINE PRODUCTION;

EID: 0035370637     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-2236(00)01796-3     Document Type: Review

References (18)

1. Schenk D., et al. Immunization with Aβ attenuates Alzheimer's disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
2. Helmuth L. Further progress on a β-amyloid vaccine. Science. 289:2000;375.
3. Morgan D., et al. Vaccination with Aβ peptide prevents memory deficits in an animal model of Alzheimer's disease. Nature. 408:2000;982-985.
4. Holcomb L., et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4:1998;97-100.
5. Wengenack T.M., et al. Quantitative histological analysis of amyloid deposition in Alzheimer's double transgenic mouse brain. Neuroscience. 101:2000;939-944.
6. Routtenberg A. Measuring memory in a mouse model of Alzheimer's disease. Science. 277:1997;839-841.
7. Guenette S.Y., Tanzi R.E. Progress toward valid transgenic mouse models for Alzheimer's disease. Neurobiol. Aging. 20:1999;201-211.
8. Arendash G.W., et al. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res. 891:2001;42-53.
9. Gordon, M.N. et al. Correlation between cognitive deficits and Aβ deposits in transgenic APP+PS1 mice. Neurobiol. Aging (in press).
10. Holcomb L.A., et al. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav. Genet. 29:1999;177-185.
11. Chen G., et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature. 408:2000;975-979.
12. Janus C., et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 408:2000;979-982.
13. Ingram D.K. Analysis of age-related impairments in learning and memory in rodent models. Ann. New York Acad. Sci. 444:1985;313-331.
14. Klaver C.C., et al. Is age-related maculopathy associated with Alzheimer's disease? The Rotterdam Study. Am. J. Epidemiol. 150:1999;963-968.
15. Blanks J.C., et al. Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol. Aging. 17:1996;377-384.
16. Mucke L., et al. High-level neuronal expression of Aβ1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20:2000;4050-4058.
17. Wong T.P., et al. Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J. Neurosci. 19:1999;2706-2716.
18. Takeuchi A., et al. Age-related Aβ deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and Aβ precursor protein Swedish mutant is not associated with global neuronal loss. Am. J. Pathol. 157:2000;331-339.